Clinical lymphoma, myeloma & leukemia · 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database.
СтатьяСравнительное исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Varghese Julia, Venner Christopher P, Louzada Martha, Reece Donna, White Darrell, Sharma Smriti, Su Jiandong, Chu Michael P, Jimenez-Zepeda Victor H, McCurdy Arleigh, Song Kevin, Mian Hira, Sebag Michael, Stakiw Julie, Reiman Anthony, Kotb Rami, Aslam Muhammad, Kaedbey Rayan, Bergstrom Debra, Gul Engin, LeBlanc Richard
Аннотация
BACKGROUND: In multiple myeloma, t(11;14) confers a unique biology including a lymphoplasmacytic phenotype and an association with plasma cell leukemia. Some studies report a favourable while others a worse prognosis, compared to non-t(11;14) cases. Dependence of t(11;14) cells on the BCL2 pathway offers a potential therapeutic target.
METHODS: We performed a matched comparison of real-world outcomes in patients with and without t(11;14) as a benchmark for future therapy targeting BCL2. A retrospective observational study was conducted using the Canadian Myeloma Research Group database between 2004-2022. FISH and karyotype studies were used to identify which patients carried the t(11;14) versus those who did not. Those found to harbour the t(11;14) were matched one-to-one with a non-t(11;14) cohort based on age at line 1 of therapy, gender, year of diagnosis and history of autologous stem cell transplant.
RESULTS: Compared with non-t(11;14), those with t(11;14) had similar PFS during line 1 (44 (95%CI: 32-51) months vs. 44 (95%CI: 36-65) months), but shorter PFS in line 2 (18 (95% CI: 11-22) months vs. 32 (95%CI: 23-49) months) resulting in a shorter PFS2 (55 (95%CI: 45-87 months vs. 83 (95%CI: 74-115) months).
CONCLUSIONS: Although not yet translating into a worse OS, this merits longer follow up. This suggests the need for optimal treatment choice and sequencing at relapse within this unique cytogenetic group. Our large, matched comparison in real-world t(11;14) myeloma serves as an important benchmark for studies looking at targeted BCL2 inhibitors in these patients.
METHODS: We performed a matched comparison of real-world outcomes in patients with and without t(11;14) as a benchmark for future therapy targeting BCL2. A retrospective observational study was conducted using the Canadian Myeloma Research Group database between 2004-2022. FISH and karyotype studies were used to identify which patients carried the t(11;14) versus those who did not. Those found to harbour the t(11;14) were matched one-to-one with a non-t(11;14) cohort based on age at line 1 of therapy, gender, year of diagnosis and history of autologous stem cell transplant.
RESULTS: Compared with non-t(11;14), those with t(11;14) had similar PFS during line 1 (44 (95%CI: 32-51) months vs. 44 (95%CI: 36-65) months), but shorter PFS in line 2 (18 (95% CI: 11-22) months vs. 32 (95%CI: 23-49) months) resulting in a shorter PFS2 (55 (95%CI: 45-87 months vs. 83 (95%CI: 74-115) months).
CONCLUSIONS: Although not yet translating into a worse OS, this merits longer follow up. This suggests the need for optimal treatment choice and sequencing at relapse within this unique cytogenetic group. Our large, matched comparison in real-world t(11;14) myeloma serves as an important benchmark for studies looking at targeted BCL2 inhibitors in these patients.